Novavax, Inc. · NASDAQ:NVAX
Novavax — Investor Presentation (June 2024)
22 slides from Novavax's investor presentation, Jun 6, 2024
Slide 1: Investor Presentation
Investor Presentation 1 © 2024 NOVAVAX. All rights reserved. NASDAQ: NVAX | JUNE 2024
Slide 2: Cautionary note regarding forward-looking statements
2 Cautionary note regarding forward - looking statements © 2024 NOVAVAX. All rights reserved. This presentation includes forward - looking statements . These forward - looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “
Slide 3: Company Overview
Company Overview SECTION 3 © 2024 NOVAVAX. All rights reserved.
Slide 4: Novavax corporate highlights
Novavax corporate highlights 4 © 2024 NOVAVAX. All rights reserved. Positioned for long - term value creation through commercialization of proven technology Proprietary Matrix - M TM adjuvant differentiates pipeline Rapidly advancing COVID - 19 - Influenza Combination (CIC) vaccine to Phase 3 Proven
Slide 5: Fully integrated commercial-stage biotechnology company with global presence
Fully integrated commercial - stage biotechnology company with global presence 5 © 2024 NOVAVAX. All rights reserved. Global HQ & Corporate Offices • R&D and discovery laboratories • Manufacturing operations • Commercial Novavax HQ Novavax HQ Gaithersburg, Maryland Novavax AB Uppsala, Sweden Novavax
Slide 6: Novavax's proven technology platform
Novavax’s proven technology platform 6 © 2024 NOVAVAX. All rights reserved. • Induces broad, robust neutralizing response 2 • Long - lived polyfunctional CD4+ cellular response 2 • Antigen sparing 2 • Large safety database included in approved vaccines 2,3 • Reactogenicity consistent with licensed v
Slide 7: Core vaccine products and pipeline
Core vaccine products and pipeline Significant opportunities for future development 7 © 2024 NOVAVAX. All rights reserved. 1. Authorized in select geographies under trade names Novavax COVID - 19 Vaccine, Adjuvanted; Covovax Œ ; and Nuvaxovid Œ , and authorized in the U.S. under trade name, Novavax
Slide 8: Novavax & Sanofi Collaboration and License Agreement
Novavax & Sanofi Collaboration and License Agreement SECTION 8 © 2024 NOVAVAX. All rights reserved. Announced May 10, 2024
Slide 9: Novavax and Sanofi collaboration and licensing agreement summary
Novavax and Sanofi collaboration and licensing agreement summary This agreement is a further validation of our technology platform and provides significant opportunity to drive value creation and benefit global public health 9 © 2024 NOVAVAX. All rights reserved. A multi - billion dollar potential a
Slide 10: Novavax and Sanofi collaboration and licensing agreement summary (2)
Novavax and Sanofi collaboration and licensing agreement summary (2) Upfront payment $500M Equity Investment ~$70M Total Q2 2024 ~$570M US sBLA approval (PFS) $175M US Authorization Transfer (PFS) $25M EMA MAH Transfer (PFS) $25M Pediatric Study Database Lock $50M COVID - 19 manufacturing technology
Slide 11: Novavax and Sanofi collaboration and licensing agreement summary (3)
Novavax and Sanofi collaboration and licensing agreement summary (3) Summary of financial terms Candidate selection & clinical milestones (*) $10M Launch & sales milestones $200M New vaccines Matrix - M TM New vaccines with Matrix - M TH : Eligible for royalty on net product sales in the mid single
Slide 12: Near-term Priorities
Near - term Priorities SECTION 12 © 2024 NOVAVAX. All rights reserved.
Slide 13: 2024 Near-term priorities
2024 Near - term priorities jdsfm Priority #1 Prioritize the successful transition to our new partnership with Sanofi 13 1. A portion of which we expect to be reimbursed by Sanofi under the collaboration and licensing agreement © 2024 NOVAVAX. All rights reserved. jdsfm Priority #2 Continue to expan
Slide 14: Well-positioned to deliver a differentiated CIC vaccine and capture market opportunity
14 © 2024 NOVAVAX. All rights reserved. Well - positioned to deliver a differentiated CIC vaccine and capture significant market opportunity Leverage Proven Technology Platform 1. Protein Receptivity Study (January 2022). 2. IQVIA Demand Study (2023). 3. IPSOS syndicated Awareness, Trial and Usage t
Slide 15: CIC and stand-alone influenza Phase 3 program design
vs Clinical program has been modified to seek licensure for both CIC and Stand - alone influenza ( tNIV ) in ≥ 60 yo Part B: Stand - alone Influenza (tNIV) Designed to achieve accelerated approval endpoints for both products with no change to timelines tIIV Novavax COVID - 19 + CIC Placebo + tNIV Pl
Slide 16: R&D and SG&A expense trends & 2024 guidance
R&D and SG&A expense trends & 2024 guidance $1.7B Creating a more lean and agile organization • Reduced workforce by 30 % compared to the first quarter of 2023 • Targeting FY 2024 R&D and SG&A expenses of $700 - $ 75 0 million • Preparing to initiate an additional cost reduction program to reduce 20
Slide 17: Setting the stage for a stronger U.S. commercial performance in 2024+
Setting the stage for a stronger U.S. commercial performance in 2024+ 2024 - 2025 Vaccination Season Goals Single - dose pre - filled syringe Product Presentation Timing of Product at Distribution Centers Ready to be Shipped Market Access Marketing Efforts 17 © 2024 NOVAVAX. All rights reserved. Tar
Slide 18: COVID commercial execution in rest of world in 2024+
COVID - 19 commercial execution in rest of world in 2024+ Europe Australia, New Zealand and Canada 18 © 2024 NOVAVAX. All rights reserved. • Seeing a more normal, non - pandemic consumer demand pattern • Delivering unit - dose presentation • Focusing on key countries driving business : Italy, Spain
Slide 19: Financial Guidance and Corporate Milestones
Financial Guidance and Corporate Milestones SECTION 19 © 2024 NOVAVAX. All rights reserved.
Slide 20: Full year 2024 financial guidance
Full year 2024 financial guidance $ in millions FY 2024 Combined Revenue & Sanofi Agreement Payments $970 - $1,170 Total Revenue 1,2 $400 - $600 Initial Sanofi Agreement Payments 3 ~$570 Combined R&D and SG&A $700 - $750 20 © 2024 NOVAVAX. All rights reserved. Total potential contract value for APAs
Slide 21: Corporate Milestones
Corporate Milestones 21 © 2024 NOVAVAX. All rights reserved. EMA, WHO and U.S. VRBPAC regulatory guidance on COVID - 19 strain selection for fall 2024 (April and June 2024) Announce Novavax and Sanofi collaboration and licensing agreement (May 2024) Fall 2024 COVID - 19 commercial performance Initia
Slide 22: Quince Orchard Road Gaithersburg, MD 20878 United States novavax.com ir@novavax.com 22
700 Quince Orchard Road Gaithersburg, MD 20878 United States novavax.com ir@novavax.com © 2024 NOVAVAX. All rights reserved. 22